Holen Sie sich die Stockscreener-App
145.73
3.95%
5.54
Handel nachbörslich:
145.12
-0.61
-0.42%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$140.19
Offen:
$140.88
24-Stunden-Volumen:
3.40M
Relative Volume:
2.25
Marktkapitalisierung:
$16.26B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$239.11M
KGV:
69.08
EPS:
2.1097
Netto-Cashflow:
$492.62M
1W Leistung:
+17.67%
1M Leistung:
+24.73%
6M Leistung:
+68.51%
1J Leistung:
+70.88%
1-Tages-Spanne:
$140.20
$147.50
1-Wochen-Bereich:
$120.89
$147.50
52-Wochen-Spanne:
$81.22
$147.50
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, NTRA, IQV, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
145.73 | 13.87B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
648.43 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
208.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
345.34 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
268.82 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
153.69 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-12-09 | Eingeleitet | Goldman | Neutral |
| 2025-10-16 | Eingeleitet | Guggenheim | Neutral |
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
(RVTY) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revvity Inc Share PriceRVTY, RNS News, Articles, Quotes, & Charts (NYSE:RVTY) - Proactive financial news
Revvity, Inc. rStock (RRVTY) Price Prediction for 2026 to 2031 - bybit.com
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery - Yahoo Finance
Revvity Inc. stock gains momentum as UBS adjusts price target and Q2 2026 revenue edges higher - ad-hoc-news.de
Top Revvity (RVTY) Competitors 2026 - MarketBeat
Revvity stock heads into the open after a 2.35% slide - ad-hoc-news.de
Revvity Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Revvity (RVTY) Receives a New Rating from UBS - The Globe and Mail
Revvity stock heads into the open after a 2.5% Nasdaq drop - ad-hoc-news.de
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity, Inc. entered into a definitive agreement to acquire Human Cell Design SAS. - marketscreener.com
Revvity to acquire Human Cell Design for metabolic research tools By Investing.com - Investing.com Australia
RVTY Assumes Rating by UBS -- Price Target Raised to $140 - GuruFocus
Revvity at Wells Fargo 21st annual healthcare conference: growth and margin focus - Investing.com India
Revvity Acquiring French Firm Human Cell Design - GenomeWeb
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition - Benzinga
UBS Downgrades Revvity to Neutral From Buy, Adjusts Price Target to $140 From $120 - marketscreener.com
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery - BioSpace
Revvity, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
RVTY Looks 8.1% Overvalued on GF Value™ - GuruFocus
RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow - GuruFocus
Revvity to Acquire Human Cell Design - marketscreener.com
Revvity to acquire Human Cell Design - TradingView
Revvity to acquire Human Cell Design for metabolic research tools - investing.com
A planned Revvity deal would add human pancreatic cells for diabetes research - Stock Titan
Revvity Inc. stock slips despite solid Q2 2026 growth and cautious analyst outlook - ad-hoc-news.de
Revvity stock heads into the open after a 2.1 percent drop - ad-hoc-news.de
Revvity Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
T. Rowe Price controls over 10M Revvity (NYSE: RVTY) shares, with one fund holding about half the stake - Stock Titan
Revvity Inc. stock holds above 130 dollars as analysts stick with Hold ratings - ad-hoc-news.de
Revvity, Inc. (RVTY) Stock Analysis: Navigating Potential in the Diagnostics Sector Amid Mixed Ratings - DirectorsTalk Interviews
KeyBanc Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich? - Yahoo Finance
KeyBanc Adjusts Price Target on Revvity to $165 From $125, Maintains Overweight Rating - marketscreener.com
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Revvity Inc. stock holds near 52-week high as valuation debate intensifies - AD HOC NEWS
Baird Adjusts Price Target on Revvity to $144 From $131, Keeps Outperform Rating - marketscreener.com
Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings - finance.yahoo.com
Revvity Inc (RVTY) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 77/100 - GuruFocus
Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade - Yahoo Finance
What Makes Revvity (RVTY) a New Buy Stock - finance.yahoo.com
Revvity Faces Growth Challenges Amid Rising Competition, RBC Says - marketscreener.com
RBC Initiates Revvity at Sector Perform With $135 Price Target - marketscreener.com
RBC Capital initiates Revvity stock with Sector Perform rating By Investing.com - Investing.com Australia
RBC Capital initiates Revvity stock with Sector Perform rating - investing.com
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity, Inc. (RVTY) Stock Analysis: Navigating a 6% Potential Downside with Strategic Insights - DirectorsTalk Interviews
Revvity (RVTY) Eases to $128.8: Key Support at $122.36 Holds in FocusImbalance Zone - vinanet.vn
Revvity Inc stock hits 52-week high at 130.07 USD By Investing.com - Investing.com Nigeria
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):